CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Explore strategies to prevent wasting your credit card benefits and maximize your rewards potential.
14,940 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A federal court hearing in New York is set to scrutinize how the government plans to deliver refunds from the $166 bi...
Investors are watching Apple’s latest Siri reveal to see if it marks a meaningful AI leap or just another upgrade. Th...
As of mid-2026, the VOO vs VTI decision remains the key allocation choice for U.S. stock portfolios. This report brea...
Rising long-term care costs expose a major Medicare gap for retirees. A new survey highlights private-room bills near...
Abridge secures NVIDIA and Eli Lilly support to push an ambient AI platform toward a full hospital operating system. ...
Investors are always on the hunt for the next big winner. When a software stock looks beaten-down, opportunities and ...
Choosing between SPGM and IEFA depends on your goals: total-global exposure or a focus on developed markets outside N...
Two giants. One decision. This pipeline stock face-off: enbridge breaks down which energy infrastructure stock fits a...
AI-led gains cool as a quintet of warning signs reappear, drawing parallels to the late-2000s Nasdaq run. Investors b...
Private reverse mortgage products are outpacing HECMs, underscoring a broader push to revive the HECM for Purchase. I...
Investing in mining ETFs can add precious metals exposure without buying bullion. This guide breaks down gold miners ...